Reference Interval:
By report
|
| Note: |
When cell culture substrates (HEp-2 cells) are used, the ANA incidence is greater than 90 percent in systemic lupus erythematosus (SLE), 80 percent in Sjsyndrome and scleroderma, and 40 percent in juvenile idiopathic arthritis.
ARUP uses anti-human IgG-specific conjugate since many (20-77 percent) normal individuals have low levels (1:10 to 1:80) of ANA-IgM. Conversion of ANAs from IgM to IgG generally precedes the onset of autoimmune disease states. If clinical presentation is inconsistent with the ANA IFA result, consult ARUP for alternative testing.
Specimens are screened for ANA using ELISA. If the ELISA screen is positive, then an IFA using HEp-2 substrate will be added. If confirmed by IFA, then a titer and pattern will be reported and testing for dsDNA antibody and ENA (RNP, Smith, SSA, and SSB) antibodies will be added. Additional charges apply.
|
| CPT Code(s): |
86038 ANA; if reflexed, add 86039 ANA titer; if reflexed add 86235 RNP and 86235 Smith and 86235 SSA and 86235 SSB and 86225 dsDNA; if dsDNA reflexed, add 86256 dsDNA titer.
|
Cross References: |
Lupus (Anti-Nuclear Antibody (ANA), IgG by ELISA with Reflexes to ANA by IFA and to dsDNA, RNP, Smith, SSA, and SSB Antibodies)
, Lupus Screen (Anti-Nuclear Antibody (ANA), IgG by ELISA with Reflexes to ANA by IFA and to dsDNA, RNP, Smith, SSA, and SSB Antibodies)
, SLE Profile (Anti-Nuclear Antibody (ANA), IgG by ELISA with Reflexes to ANA by IFA and to dsDNA, RNP, Smith, SSA, and SSB Antibodies)
|